Cargando…
A Wholistic View of How Bumetanide Attenuates Autism Spectrum Disorders
The specific NKCC1 cotransporter antagonist, bumetanide, attenuates the severity of Autism Spectrum Disorders (ASD), and many neurodevelopmental or neurodegenerative disorders in animal models and clinical trials. However, the pervasive expression of NKCC1 in many cell types throughout the body is t...
Autores principales: | Delpire, Eric, Ben-Ari, Yehezkel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367773/ https://www.ncbi.nlm.nih.gov/pubmed/35954263 http://dx.doi.org/10.3390/cells11152419 |
Ejemplares similares
-
Bumetanide for autism: more eye contact, less amygdala activation
por: Hadjikhani, Nouchine, et al.
Publicado: (2018) -
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
por: Lemonnier, E, et al.
Publicado: (2017) -
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders
por: Lemonnier, E, et al.
Publicado: (2017) -
Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures
por: Ben-Ari, Yehezkel, et al.
Publicado: (2016) -
The GABA Polarity Shift and Bumetanide Treatment: Making Sense Requires Unbiased and Undogmatic Analysis
por: Ben-Ari, Yehezkel, et al.
Publicado: (2022)